Publications by authors named "Fengxin Zheng"

Claim this Profile
P
PXR activation ameliorates hyperuricemic nephropathy via NRF2 signaling.
Ting Wu, Lu Li, Yongjun Chen, Wenjie Ye, Zitao Guo, Fengxin Zheng

Pharmacol Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated aptamer-based DNAzyme motor with pattern recognition for discriminative intracellular uric acid biosensing and high-throughput GLUT9 inhibitor discovery.
Shiquan Zheng, Fengxin Zheng, Jiangtao Hao, Zean Zhao, Hanren Chen

Biosens Bioelectron· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure optimization of natural product piperine to obtain novel and potent analogs with anti-inflammation pain and urate-lowering effect.
Chunxia Liu, Wenxin Wang, Ruoyang Miao, Haoyang Chen, Ning Wang, Fengxin Zheng, Zheng Li

Eur J Med Chem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of multi-target anti-gout agents from Eurycoma longifolia Jack through phenotypic screening and structural optimization.
Zhijiao Zhang, Xiaoyu Shi, Ting Wu, Zhuhan He, Ruipeng Liang, Fengxin Zheng

Nat Commun· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-O-Methylvisammioside, a novel inhibitor of CNT2, improves hyperuricemia by inhibiting intestinal purine nucleoside absorption with a safe profile.
Suiqing Mai, Jiale Ke, Shiqin Lin, Rongrong Huang, Fengxin Zheng

Biochem Pharmacol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of cyanidin-3-O-galactoside as a novel CNT2 inhibitor for the treatment of hyperuricemia.
Fengxin Zheng, Jiale Ke, Shiqin Lin, Wenjie Ye, Zhenkun Wu

Bioorg Chem· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salinomycin, a potent inhibitor of XOD and URAT1, ameliorates hyperuricemic nephropathy by activating NRF2, modulating the gut microbiota, and promoting SCFA production.
Yong-Jun Chen, Zi-Tao Guo, Hai-Qiao Chen, Shi-Fan Zhang, Ying-Xia Bao, Feng-Xin Zheng

Chem Biol Interact· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia.
Fengxin Zheng, Suiqing Mai, Xiaolin Cen, Pei Zhao, Wenjie Ye

Bioorg Chem· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protecting against ferroptosis in hyperuricemic nephropathy: The potential of ferrostatin-1 and its inhibitory effect on URAT1.
Yongmei Li, Fengxin Zheng, Shiqi Zhong, Kunlu Zhao, Hui Liao, Qiang Zheng

Eur J Pharmacol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities.
Shengnan Li, Hui Liao, Lijun Luo, Bingxu Meng, Fengxin Zheng

Eur J Med Chem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability.
Xiaoyu Shi, Tong Zhao, Shuo Wang, Shujing Xu, Hui Liao, Fengxin Zheng

J Med Chem· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Piperine Improves Hyperuricemic Nephropathy by Inhibiting URAT1/GLUT9 and the AKT-mTOR Pathway.
Lu Li, Kunlu Zhao, Jian Luo, Jinhong Tian, Fengxin Zheng

J Agric Food Chem· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Febuxostat ameliorates APAP-induced acute liver injury by activating Keap1/Nrf2 and inhibiting TLR4/NF-κB p65 pathways.
Jinhong Tian, Shuaishuai Zhang, Lu Li, Xueman Lin, Yongmei Li, Fengxin Zheng

Exp Biol Med (Maywood)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological evaluation of a novel skeleton compound isobavachin (4',7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity.
Zean Zhao, Jian Luo, Hui Liao, Fengxin Zheng, Xinhua Chen

Bioorg Chem· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.
Zean Zhao, Jin Liu, Lin Yuan, Zichao Yang, Peihua Kuang, Fengxin Zheng

Eur J Med Chem· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insoluble Fiber in Barley Leaf Attenuates Hyperuricemic Nephropathy by Modulating Gut Microbiota and Short-Chain Fatty Acids.
Yongmei Li, Lu Li, Jinhong Tian, Fengxin Zheng, Hui Liao

Foods· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation in Transmembrane Domain 8 of Human Urate Transporter 1 Disrupts Uric Acid Recognition and Transport.
Qunsheng Lan, Ze'an Zhao, Hui Liao, Fengxin Zheng, Yongjun Chen

ACS Omega· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis